Literature DB >> 10567563

The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1.

C L Bevan1, S Hoare, F Claessens, D M Heery, M G Parker.   

Abstract

The androgen receptor is unusual among nuclear receptors in that most, if not all, of its activity is mediated via the constitutive activation function in the N terminus. Here we demonstrate that p160 coactivators such as SRC1 (steroid receptor coactivator 1) interact directly with the N terminus in a ligand-independent manner via a conserved glutamine-rich region between residues 1053 and 1123. Although SRC1 is capable of interacting with the ligand-binding domain by means of LXXLL motifs, this interaction is not essential since an SRC1 mutant with no functional LXXLL motifs retains its ability to potentiate androgen receptor activity. In contrast, mutants lacking the glutamine-rich region are inactive, indicating that this region is both necessary and sufficient for recruitment of SRC1 to the androgen receptor. This recruitment is in direct contrast to the recruitment of SRC1 to the estrogen receptor, which requires interaction with the ligand-binding domain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567563      PMCID: PMC84931          DOI: 10.1128/MCB.19.12.8383

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  80 in total

1.  Distinct classes of transcriptional activating domains function by different mechanisms.

Authors:  D Tasset; L Tora; C Fromental; E Scheer; P Chambon
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

2.  The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways.

Authors:  J J Voegel; M J Heine; M Tini; V Vivat; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

3.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

4.  The presence of a transcription activation function in the hormone-binding domain of androgen receptor is revealed by studies in yeast cells.

Authors:  A Moilanen; N Rouleau; T Ikonen; J J Palvimo; O A Jänne
Journal:  FEBS Lett       Date:  1997-07-28       Impact factor: 4.124

5.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

6.  A canonical structure for the ligand-binding domain of nuclear receptors.

Authors:  J M Wurtz; W Bourguet; J P Renaud; V Vivat; P Chambon; D Moras; H Gronemeyer
Journal:  Nat Struct Biol       Date:  1996-01

7.  The Saccharomyces cerevisiae MADS-box transcription factor Rlm1 is a target for the Mpk1 mitogen-activated protein kinase pathway.

Authors:  E Dodou; R Treisman
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

8.  Heterodimerization is mainly responsible for the dominant negative activity of amino-terminally truncated rat androgen receptor forms.

Authors:  T Ikonen; J J Palvimo; O A Jänne
Journal:  FEBS Lett       Date:  1998-07-03       Impact factor: 4.124

9.  The transcriptional activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded in a single exon.

Authors:  N J Webster; S Green; D Tasset; M Ponglikitmongkol; P Chambon
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

10.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.

Authors:  V Cavaillès; S Dauvois; F L'Horset; G Lopez; S Hoare; P J Kushner; M G Parker
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

View more
  100 in total

1.  AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Authors:  Pengfei Li; Heehyoung Lee; Shaodong Guo; Terry G Unterman; Guido Jenster; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  AIB1 polymorphisms with breast cancer susceptibility: a pooled analysis of variation in BRCA1/2 mutation carriers and non-carriers.

Authors:  Ying Zhang; Meiyan Huang; Zhenglan Zhu
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

Review 3.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 4.  Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations.

Authors:  Derek N Lavery; Iain J McEwan
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 5.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

6.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

9.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

Review 10.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.